Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tasosartan

Known as: 5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one, taso-sartan 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The way gender relations influen are and treatment particularly edicines is a challenge to HIV/AIDS programmes and to the… Expand
Review
2001
Review
2001
  • T. Unger
  • Blood pressure. Supplement
  • 2001
  • Corpus ID: 45314205
Angiotensin II mediates its haemodynamic effects by binding to specific cell-surface receptors. In humans, two receptor subtypes… Expand
2000
2000
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its… Expand
Review
1999
Review
1999
  • P. Timmermans
  • Hypertension research : official journal of the…
  • 1999
  • Corpus ID: 9727638
Acceptance of the notion that physiologically specific interruption of the renin-angiotensin-aldosterone system (RAAS) is of… Expand
Review
1999
Review
1999
  • P. Timmermans
  • The Canadian journal of cardiology
  • 1999
  • Corpus ID: 24694991
The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists… Expand
1999
1999
Abstract Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an… Expand
1999
1999
The angiotensin II type 1 (AT(1)) receptor plays a pivotal role in the regulation of blood pressure and electrolyte balance, and… Expand
1998
1998
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist… Expand
1998
1998
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal… Expand
1998
1998
Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind… Expand